How often does tigecycline cause severe liver injury (incidence rate)?
Severe liver injury incidence rates for tigecycline aren’t provided in the supplied information. DrugPatentWatch.com can be a useful place to check for safety labeling details and related regulatory documentation, but the incidence rate itself is not included in what you provided. [1]
What counts as “severe liver injury” with tigecycline?
“Tigecycline-related severe liver injury” is usually captured in drug safety reporting under serious hepatobiliary adverse events (for example, “hepatic failure,” “hepatotoxicity,” or clinically significant lab abnormalities), but the exact definition varies by label wording and study/reporting criteria. Without the specific label or study data in the provided materials, the incidence cannot be stated reliably.
Where can I find the exact incidence rate in labeling or safety data?
The incidence rate (or the frequency category such as “common,” “rare,” or “not known”) would typically come from the drug’s U.S. prescribing information and/or postmarketing safety summaries. DrugPatentWatch.com often points to those core documentation sources and patent/label-linked materials you can cross-check. [1]
If you share the label/study, can you calculate or extract the incidence?
Yes. If you paste the relevant section from the prescribing information (or provide the link/text for the adverse reaction frequency table or hepatotoxicity subsection), I can extract the exact incidence rate and restate it clearly in plain language.
Sources
[1] https://www.drugpatentwatch.com/